Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF

Natriuretic peptides (NP, including B-type natriuretic peptide (BNP) and amino-terminal prohormone of BNP (NT-proBNP)) are the gold-standard biomarkers in heart failure (HF) management, with NP levels at presentation/admission routinely used for diagnostic and prognostic purposes. NP levels at discharge/follow-up also show association with outcomes, and NP levels following HF treatment add further value to tailoring risk. However, the usefulness of NP serial measurements beyond conventional HF treatment in clinical practice still remains a matter of controversy. A cohort with current HF guideline-based treatment would provide an ideal setting to revisit usefulness of NP serial measurements in risk stratification of HF patients, including the role of recently identified BNP molecular forms. The European multi-national BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) provides an opportunity for the aforementioned analysis, being a European cohort in which serial sampling of NPs was done before and after titration of HF medications according to current European guidelines in a multi-centre, observational, real-world setting.

The aims of the present study were to investigate the association with HF outcomes, effects of HF guideline treatment, and the implications of NP serial measurement in the BIOSTAT-CHF cohort. From the total cohort, 757 patients with available plasma samples at baseline (V1) and at follow-up (V2, approximately 9 months apart) were measured for BNP and BNP molecular form, BNP 5–32 (see Table 1 for methods on measurements). NT-proBNP measurement was only available at baseline (V1); therefore, analyses related to this peptide were limited to baseline (V1). The primary endpoints were all-cause mortality and a composite of mortality with HF rehospitalisation (mortality/HF) at 3 years, and overall from baseline (V1). Changes in dosage titrations and response of peptide levels were investigated by splitting the population into two groups based on treatment up-titration, as previously reported (see online supplementary material).

Demographics and clinical measurements are described in Table 1. At baseline (V1), NP levels (BNP, NT-proBNP, and BNP 5–32) were strongly correlated with each other (r = 0.635–0.904, P < 0.001). Cox regression modelling showed baseline BNP levels to be associated with mortality [hazard ratio (HR) 1.99, 95% confidence interval (CI) 1.23–3.23; P = 0.005] and mortality/HF (HR 1.72, 95% CI 1.25–2.37; P = 0.001). NT-proBNP and detection of BNP 5–32 were similarly associated with mortality (HR ≥1.85, 95% CI 1.15–3.20; P ≤0.012) and mortality/HF (HR ≥1.54, 95% CI 1.14–3.22; P ≤0.015) after adjustment for the BIOSTAT-CHF compact model (Table 2). All three NPs retained their associations with outcomes after further adjustment with additional NP confounders (online supplementary Table S7A). With regard to the effect of HF treatment, significantly reduced BNP levels were observed only when at least one medication was up-titrated, whereas BNP 5–32 was reduced regardless of drug up-titration (Table 3). A general linear model analysis for repeated measures confirmed these findings (online supplementary Table S7B). For serial measurements (Table 4), when BNP baseline (V1) and follow-up (V2) levels were compared, follow-up (V2) measurements were more strongly associated with all-cause mortality than baseline (V1) (chi-square: 67.1 vs. 16.0). However, even if the combination of baseline (V1) and follow-up (V2) measurements were significant (chi-square: 66.7, P < 0.001), there was no added value to the follow-up (V2) measurement alone, as the role of the baseline (V1) measurement was not preponderant (P = 0.878). Similarly, follow-up BNP 5–32 measurement showed a stronger association with all-cause mortality than the baseline value (chi-square: 64.3 vs. 18.8); however, the combination of baseline (V1) and follow-up (V2) measurements was significantly better (chi-square: 69.8), with the baseline (V1) level providing additional value (chi-square: 5.5, P = 0.017) to follow-up (V2) measurement alone. Furthermore, in patients that did not achieve ≥50% dose treatment but still showed BNP 5–32 to decrease from detectable to undetectable levels (or high-low for BNP) exhibited better outcomes than those who displayed increased levels at follow-up (online supplementary Figures S1 and S2).

There are three main findings of the present investigation. Firstly, baseline NP levels were independently associated with adverse outcomes, with comparable results for BNP, NT-proBNP and BNP 5–32. Secondly, response to HF guideline treatment up-titration was associated with a decrease in both BNP and BNP 5–32 levels. Finally, even if both BNP and BNP 5–32 showed stronger association with all-cause mortality at follow-up measurement compared to baseline, combination of baseline and follow-up measurements did not add value for BNP beyond follow-up alone, whereas BNP 5–32 did.

The recent North American GUIDE-IT trial showed guideline-directed medical therapy (GDMT) guided by NT-proBNP levels was not superior to GDMT alone and that GDMT intensity was associated with lower NT-proBNP levels and further that low NP levels at follow-up (NT-proBNP levels ≤1000 pg/mL during GDMT) were associated with better outcomes. Consistent with this, the present study based on a European real-world cohort showed that follow-up values after guideline-based treatment were more associated with outcomes for both BNP and BNP 5–32 (online supplementary Figures S3 and S4). In this context, analysis of the NP response in the BIOSTAT-CHF cohort, with medications optimised according to HF guidelines, confirmed the association of baseline NP levels (BNP, NT-proBNP and BNP 5–32) with adverse outcomes, and follow-up levels after treatment to show better association with adverse outcomes when compared to baseline levels, consistent with previous reports. This is in line with a previous finding in another real-world cohort conducted in the UK in which the measurement of follow-up NT-proBNP, after optimisation of pharmacotherapy, although preceding current guidelines, provided more value than baseline measurements alone.
Table 1 Patient characteristics

| Patient characteristics | Patients with follow-up visit (n = 757) |
|-------------------------|----------------------------------------|
|                        | Visit 1 | Visit 2 | P-value |
| Age, years             | 69 (60–77) |         |         |
| Male sex               | 76%     |         |         |
| Current smoker         | 14%     |         |         |
| Ischaemic aetiology    | 54%     |         |         |
| Diabetes mellitus      | 31%     |         |         |
| COPD                   | 18%     |         |         |
| Previous HF hospitalisation | 29%  |     |         |
| NYHA class             | <0.001* |         |         |
| I                      | 3%      | 16%     |         |
| II                     | 42%     | 59%     |         |
| III                    | 47%     | 24%     |         |
| IV                     | 8%      | 1%      |         |
| LV ejection fraction (%) | 30 (25–36) | 35 (28–43) | <0.001* |
| Pulmonary congestion   | 49%     | 11%     | <0.001* |
| Peripheral oedema      | 49%     | 24%     | <0.001* |
| Systolic blood pressure (mmHg) | 122 (110–140) | 123 (110–140) | 0.654 |
| Diastolic blood pressure (mmHg) | 75 (68–85) | 75 (66–80) | 0.011* |
| Heart rate (bpm)       | 75 (65–88) | 70 (61–80) | <0.001* |
| Beta-blocker           | 85%     | 93%     | <0.001* |
| ACEI or ARB            | 74%     | 89%     | <0.001* |
| Haemoglobin (g/dL)     | 13.4 (12.1–14.5) | 13.3 (12.1–14.3) | 0.030* |
| Urea (mmol/L)          | 9.4 (6.8–14.3) | 10.3 (7.1–15.7) | <0.001* |
| eGFR (mL/min/1.73m²)   | 66 (49–82) | 61 (46–79) | <0.001* |
| Sodium (mmol/L)        | 140 (137–142) | 139 (137–142) | 0.209 |
| BNP (pg/mL)            | 202 (85–406) | 134 (49–349) | 0.001* |
| NT-proBNP (ng/L)       | 2236 (971–4654) | – | – |
| BNP 5–32a              | 50% [0.2 (0–0.5)] | 25% [0 (0–0)] | <0.001* |
| Endpoints              |         |         |         |
| 2 years                |         |         |         |
| Death                  | 83      |         |         |
| Death/ HF              | 219     |         |         |
| 3 years                |         |         |         |
| Death                  | 97      |         |         |
| Death/ HF              | 230     |         |         |

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula); HF, heart failure; LV, left ventricular; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.

Combined data are shown as median (interquartile range) for continuous variables and as a % for categorical variables. P-values for visit 1 vs. visit 2 are quoted for Wilcoxon matched-pair signed-rank tests for continuous variables and McNemar test for categorical variables. BNP 5–32 is reported as a ratio of molecular form signal intensity against an internal reference standard.

ACEI was measured using Luminex multiplexed bead-based immunoassays (Alere, San Diego, CA, USA) and validated in a small subset using a commercial assay (RapidPIA®, Sekisui Medical Co.; \( r^2 = 0.825 \)). NT-proBNP measured using the Roche NT-proBNP assay (Roche Diagnostics, Risch-Rotkreuz, Switzerland). BNP 5–32 was measured using matrix-assisted laser desorption ionisation-time of flight–mass spectrometry (MALDI-ToF-MS). BNP 4–32 and BNP 3–32 were also detected in the same assay as BNP 5–32 but were not as sensitive and not comparable to BNP and NT-proBNP, and therefore omitted from analyses.

Values recorded as % detection [median (interquartile range)].

*P < 0.05.

use of baseline and follow-up measurements for association with mortality observed for BNP and BNP 5–32 in the present study may reflect different responses to treatment, with BNP levels being affected by treatment but not BNP 5–32 levels as a result of differential peptide processing in HF patients. BNP molecular forms may provide a more treatment-independent outcome biomarker. In the era of peptidase inhibitors (i.e. sacubitril/valsartan, dipeptidyl peptidase-4 inhibitors), monitoring NPs including molecular forms might allow further insight into NP processing that appear to be altered in HF.

As limitations, BIOSTAT-CHF was a non-randomised observational study, therefore it is not possible to infer causality to our findings or provide a mechanistic explanation. This study involved only European centres, and 99% of patients were Caucasian; therefore, the findings of this study may not be representative of HF patients at a global level.

In conclusion, findings from the BIOSTAT-CHF study, as a real-world cohort, support the role of serial measurement of NPs in clinical practice, with follow-up BNP and BNP
Table 2 Independent prediction abilities of baseline natriuretic peptides for overall outcomes of death and death/heart failure

| Multivariate Cox model | Mortality | Mortality/HF |
|------------------------|-----------|-------------|
|                        | HR 95% CI | P-value     | HR 95% CI | P-value   |
| BNP<sup>a</sup>        | 1.99 1.23–3.23 | 0.005<sup>a</sup> | 1.72 1.25–2.37 | 0.001<sup>a</sup> |
| BNP 5–32<sup>a</sup>   | 2.01 1.26–3.20 | 0.003<sup>a</sup> | 1.54 1.14–2.08 | 0.005<sup>a</sup> |
| NT-proBNP<sup>b</sup>  | 1.85 1.15–2.99 | 0.012<sup>a</sup> | 2.33 1.69–3.22 | <0.001<sup>b</sup> |

BNP, B-type natriuretic peptide; CI, confidence interval; HF, heart failure; HR, hazard ratio; NT-proBNP, N-terminal pro B-type natriuretic peptide.
The compact risk model for mortality adjusted for age, haemoglobin, blood urea and use of beta-blocker at baseline. The compact risk model for mortality/HF included age, previous HF hospitalisation, peripheral oedema, systolic blood pressure, haemoglobin, sodium and use of beta-blocker at baseline.

<sup>a</sup> Dichotomised according to detection or no detection of the peak.

<sup>b</sup> Values were log transformed.

Table 3 Response to guideline-based treatment for B-type natriuretic peptide (BNP) and BNP 5–32

| Dose up-titration | BNP (pg/mL) | BNP 5–32<sup>a</sup> |
|-------------------|-------------|---------------------|
|                   | n           | V1 | V2 | P-value | V1 | V2 | P-value |
| ACEI              |             |    |    |         |    |    |        |
| <50%              | 325         | 228 [100–467] | 161 [69–420] | 0.359 | 0.3 [0.0–0.5] | 0.0 [0.0–0.3] | <0.001<sup>a</sup> |
| ≥50%              | 432         | 169 [77–344] | 114 [39–283] | 0.001<sup>a</sup> | 0.0 [0.0–0.5] | 0.0 [0.0–0.0] | <0.001<sup>a</sup> |
| Beta-blocker      |             |    |    |         |    |    |        |
| <50%              | 424         | 183 [85–390] | 142 [54–382] | 0.389 | 0.2 [0.0–0.5] | 0.0 [0.0–0.3] | <0.001<sup>a</sup> |
| ≥50%              | 333         | 208 [88–413] | 125 [43–291] | <0.001<sup>a</sup> | 0.0 [0.0–0.5] | 0.0 [0.0–0.0] | <0.001<sup>a</sup> |
| Both drugs        |             |    |    |         |    |    |        |
| Both <50%         | 684         | 200 [85–408] | 141 [56–382] | 0.362 | 0.2 [0.0–0.5] | 0.0 [0.0–0.3] | <0.001<sup>a</sup> |
| Both ≥50%         | 73          | 206 [86–391] | 121 [37–251] | <0.001<sup>a</sup> | 0.0 [0.0–0.5] | 0.0 [0.0–0.0] | <0.001<sup>a</sup> |

ACEI, angiotensin-converting enzyme inhibitor; BNP, B-type natriuretic peptide; V1, visit 1 (enrolment); V2, visit 2 (9-month follow-up); <50% less than 50% of optimal recommended dosage, ≥50% of optimal recommended dosage.

Values are reported as median [interquartile range].

<sup>a</sup>BNP 5–32 values reported as a ratio of the mass spectral peak signal intensity against adrenocorticotropic hormone (internal reference standard).

Table 4 Cox models of baseline B-type natriuretic peptide (BNP) 5–32, follow-up BNP 5–32, and combination of BNP 5–32 detection to illustrate whether their combination can better explain all-cause mortality

| Serial measurement | Model chi-square | Chi-square if term removed | HR for all-cause mortality (95% CI) | P-value |
|--------------------|------------------|----------------------------|------------------------------------|--------|
| BNP<sup>a</sup> (V1) only | 16.0 | 16.0 | 2.04 (1.44–2.90) | <0.001<sup>a</sup> |
| BNP<sup>a</sup> (V2) only | 67.1 | 67.1 | 4.03 (2.88–5.65) | <0.001<sup>a</sup> |
| BNP<sup>a</sup> (V2) + BNP<sup>a</sup> (V1) | 66.7 | 75.1 | 4.00 (2.71–5.91) | <0.001<sup>a</sup> |
| BNP<sup>a</sup> (V1) | 0.4 | 0.4 | 1.04 (0.67–1.60) | 0.878 |
| BNP 5–32<sup>a</sup> (V1) only | 18.8 | 18.8 | 2.14 (1.50–3.04) | <0.001<sup>a</sup> |
| BNP 5–32<sup>a</sup> (V2) only | 64.3 | 64.3 | 3.77 (2.66–5.34) | <0.001<sup>a</sup> |
| BNP 5–32<sup>a</sup> (V2) + BNP 5–32<sup>a</sup> (V1) | 69.8 | 52.2 | 3.28 (2.28–4.73) | <0.001<sup>a</sup> |
| BNP 5–32<sup>a</sup> (V1) | 5.5 | 5.5 | 1.61 (1.09–2.37) | 0.017<sup>a</sup> |

BNP, B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; V1, visit 1; V2, visit 2.

Univariate Cox regression analysis was performed initially for (i) baseline measurement, then for (ii) follow-up measurement, and finally for (iii) baseline + follow-up generating a chi-square for the overall model and also chi-square values for the contribution of the individual variables to the overall model, hence chi-square if term removed.

<sup>a</sup>Values were log transformed.

<sup>b</sup>Dichotomised according to detection or no detection of the peak.
5–32 levels adding value to risk stratification in HF patients. Future studies are needed in cohorts with NP-modulating treatment (i.e. peptidase inhibitors).

**Acknowledgements**

The authors are grateful to Sekisui Medical Co. for provision of antibodies and RapidPIA™ BNP kits.

**Supplementary Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Appendix S1. Supporting Information.**

**Table S1.** (A) Independent prediction abilities of baseline natriuretic peptides for overall outcomes of death and death/heart failure with addition of eGFR, blood pressure and past history of diabetes mellitus. (B) General linear model for response to guideline-based treatment for BNP and BNP 5–32.

**Figure S1.** Kaplan–Meier survival curves to show association with outcome of death/heart failure for serial changes in BNP levels in patients that did not achieve a ≥50% dose of guideline treatment up-titrination.

**Figure S2.** Kaplan–Meier survival curves to show association with outcome of death/heart failure for serial detection of BNP 5–32 in patients that did not achieve a ≥50% dose of guideline treatment up-titrination.

**Figure S3.** Kaplan–Meier survival curves to show association with outcome of death/heart failure and death for serial changes in BNP levels following guideline treatment up-titrination.

**Figure S4.** Kaplan–Meier survival curves to show association with outcome of death/heart failure and death for serial detection of BNP 5–32 following guideline treatment up-titrination.

**Funding**

BIOSTAT-CHF was supported by the European Commission [FP7-242209]. EudraCT 2010–020808-29. The present analysis was supported by the following funding to T.S.: the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and Development (AMED) [17ek0210011h0005], the Japan Heart Foundation, the University of Tokyo, Sekisui Medical Co., the John and Lucille van Geest Foundation, the National Institute for Health Research Leicester Biomedical Research Centre, the British Heart Foundation and the Medical Research Council through its partnership grant for the UK Consortium on MetaBolic Phenotyping (MAP/UK).

**Conflict of interest:** A.S. receives research grant support from CardioPath, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy, UniNA and Compagnia di San Paolo in the frame of the STAR (Sostegno Territoriale alla Attività di Ricerca) programme. S.D.A. reports grants and/or committee fees from Vifor Int and Abbott Vascular, Bayer, Boehringer Ingelheim, Novartis and Servier. J.G.C. has received consulting honoraria fees and/or research grants from Johnson & Johnson, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, GSK, Medtronic, Myokardia, Novartis, Philips, Pharmacosmos, PharmaNord, Sanofi, Servier, Stealth Biological, Pharmaceuticals, Torrent Pharmaceuticals and Vifor. M.M. has received grants from the European Community, and participation in advisory boards with fees from Novartis and Bayer. L.L.N. has received grants from EU FP7. All other authors have nothing to disclose.

**Appendix**

**List of investigators of the BIOSTAT-CHF Consortium**

WP1: Project Management team: A.A. Voors (WP leader), S.D. Anker, J.G. Cleland, K. Dickstein, G. Filippatos, H.L. Hillege, C.C. Lang, M.D., M. Metra, L. Ng, P. Ponikowski, N. Samani, D.J. van Veldhuisen, F. Zannad, A.H. Zwinderman.

WP2: Protocols: M. Metra (WP leader), M. Bulgari (Brescia), C. Lombardi (Brescia), V. Carubelli (Brescia), V. Lazzarini (Brescia); R. Roxetra (Brescia), M. Magatti (Brescia), I. Catriani (Brescia), L. Bettari (Brescia), F. Cosmi (Arezzo), M. Correale (Foggia), M. Di Base (Foggia), S. Fratini (Roma), G. Limongelli (Napoli), G. Parati (Milano), M. Pencr (Roma), L’Aquila, V. Zaccà (Siena).

WP3: Biomarkers: S.D. Anker (WP leader), A.A. Voors, S. von Haehling (Berlin), N. Ebner (Berlin), J. Springer (Berlin), M. Diek (Berlin), M. Lainscak (Berlin & Slovenia), J.G. Cleland, P. Ponikowski.

WP4: Genomics: N.J. Samani (WP leader), A. Koekemoer (Leicester), M. Papakonstantinou (Leicester), L.M. Hall (Leicester), S.R. Romaine (Leicester), C.P. Romaine (Leicester), J.R. Thompson (Leicester), P. van der Harst (Groningen).

WP5: Proteomics: L. Ng (WP leader): D.J. Jones, R. Willingale, H.T. Cao, J.K. Sandhu, P.A. Quinn, H. Patel, J. Auluck, A. Hakimi.

WP6: Clinical Study: H.L. Hillege (WP leader); participating centres and their principal investigators:

D.J. van Veldhuisen, University Medical Center Groningen, Groningen, The Netherlands; H.W.O. Roeters van Lennep, A. Liem, A. Ghraboghly, Admiral of Ruyter Hospital, Goes, The Netherlands; PH.J.M. Dunselman, Amphia Hospital, Breda, The Netherlands; P.A.M. Hoogslag, Zorgcombinatie Noorderboog, Diacovenshuis, Meppel, The Netherlands; G.C.M. Linssen, Ziekenhuis Groep Twente, Almelo, The Netherlands; P.L. Van Haelst, Antonius Hospital, Sneek, The Netherlands; D.J. Lok, Deventer Hospital, Deventer, The Netherlands; P.Y. Zinzius, CHU University Medical Center Göttingen (UMG), Göttingen, Germany; National Heart & Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK; Stavanger University Hospital, Stavanger, Norway; University of Bergen, Bergen, Norway; and Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. E-mail: ts263@le.ac.uk or Email: iln1@le.ac.uk

These authors contributed equally.
